<?xml-stylesheet type='text/xsl' href='ctgovTransform.xsl'?>
<CT.GOV_Trial requestNumber="5837">
  <stage>Registered</stage>
  <submitdate>24/02/2016</submitdate>
  <approvaldate>24/02/2016</approvaldate>
  <nctid>NCT02743221</nctid>
  <trial_identification>
    <studytitle>A Study Evaluating S 95005 Plus Bevacizumab and Capecitabine Plus Bevacizumab in Patients With Previously Untreated Colorectal Cancer Who Are Non-eligible for Intensive Therapy</studytitle>
    <scientifictitle>An Open-label, Randomised, Non-comparative Phase 2 Study Evaluating S 95005 (TAS-102) Plus Bevacizumab and Capecitabine Plus Bevacizumab in Patients With Previously Untreated Metastatic COlorectal Cancer Who Are Non-eligible for Intensive Therapy (TASCO1 Study).</scientifictitle>
    <utrn />
    <trialacronym>TASCO1</trialacronym>
    <secondaryid>CL2-95005-002</secondaryid>
  </trial_identification>
  <conditions>
    <healthcondition>Metastatic Colorectal Cancer</healthcondition>
    <conditioncode>
      <conditioncode1>Cancer</conditioncode1>
      <conditioncode2>Bowel - Back passage (rectum) or large bowel (colon)</conditioncode2>
    </conditioncode>
  </conditions>
  <interventions>
    <interventions>Treatment: drugs - Trifluridine/tipiracil hydrochloride (S 95005)
Treatment: drugs - Capecitabine
Treatment: drugs - Bevacizumab
Treatment: drugs - Bevacizumab

Experimental: S 95005 + bevacizumab - 

Active Comparator: Capecitabine + bevacizumab - 


Treatment: drugs: Trifluridine/tipiracil hydrochloride (S 95005)
film-coated tablets containing 15mg of trifluridine and 7.065mg of tipiracil hydrochloride, or 20mg of trifluridine and 9.42mg of tipiracil hydrochloride, taken orally twice a day at the dose of 35 mg/m2/dose, until a discontinuation criterion is met

Treatment: drugs: Capecitabine
Capecitabine film-coated tablets containing 150 mg or 500 mg of capecitabine taken orally twice a day at the dose of 1250 mg/m2/dose, until a discontinuation criterion is met

Treatment: drugs: Bevacizumab
concentrate for solution for infusion containing 25mg/ml of bevacizumab administered intravenously at the dose of 5 mg/kg, until a discontinuation criterion is met

Treatment: drugs: Bevacizumab
concentrate for solution for infusion containing 25mg/ml of bevacizumab administered intravenously at the dose of 7.5 mg/kg, until a discontinuation criterion is met

</interventions>
    <comparator />
    <control />
    <interventioncode>Treatment: drugs</interventioncode>
  </interventions>
  <outcomes>
    <primaryOutcome>
      <outcome>Progression free survival (PFS)</outcome>
      <timepoint>Up to 12 months.</timepoint>
    </primaryOutcome>
    <secondaryOutcome>
      <outcome>Overall Response Rate (ORR)</outcome>
      <timepoint>Up to 12 months.</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Duration of Response (DR)</outcome>
      <timepoint>Up to 12 months.</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Disease control rate (DCR)</outcome>
      <timepoint>Up to 12 months.</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Overall Survival (OS)</outcome>
      <timepoint>Up to 2 years.</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Safety and tolerability assessed by incidence of Adverse Events</outcome>
      <timepoint>Up to 12 months.</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Safety and tolerability assessed by laboratory tests</outcome>
      <timepoint>Up to 12 months.</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Safety and tolerability assessed by physical examination</outcome>
      <timepoint>Up to 12 months.</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Safety and tolerability assessed by performance status (ECOG)</outcome>
      <timepoint>Up to 12 months.</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Safety and tolerability assessed by vital signs</outcome>
      <timepoint>Up to 12 months.</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Safety and tolerability assessed by 12-leads ECG parameters</outcome>
      <timepoint>Up to 12 months.</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Quality of Life assessed by a quality of life questionnaire.</outcome>
      <timepoint>Up to 12 months.</timepoint>
    </secondaryOutcome>
  </outcomes>
  <eligibility>
    <inclusivecriteria>-  Written informed consent obtained.

          -  Male or Female participant aged =18 years old.

          -  Has ECOG performance status of 0, 1 or 2 at the time of the randomisation.

          -  Has definitive histologically or cytologically confirmed adenocarcinoma of the colon
             or rectum.

          -  RAS status must have been determined (mutant or wild).

          -  Has at least one measurable metastatic lesion.

          -  No previous systemic anticancer therapy for unresectable metastatic colorectal cancer.

          -  Previous adjuvant (or neoadjuvant for patients with rectal cancer) chemotherapy is
             allowed only if if it has been completed more than 6 months before start of study
             treatment.

          -  Patient is not a candidate for combination chemotherapy with irinotecan or
             oxaliplatin, or for curative resection of metastatic lesions.

          -  Is able to take medication orally (i.e., no feeding tube).

          -  Has adequate organ function.

          -  Coagulation parameters in normal limit (or in therapeutic limit for patients treated
             with anticoagulant drugs).

          -  Women of childbearing potential must have been tested negative in a serum pregnancy
             test. Female participants of childbearing potential and male participants with
             partners of childbearing potential must agree to use a highly effective method of
             birth control. Women and female partners using hormonal contraceptive must also use a
             barrier method.

          -  Is willing and able to comply with scheduled visits and study procedures.</inclusivecriteria>
    <inclusiveminage>18</inclusiveminage>
    <inclusiveminagetype>Years</inclusiveminagetype>
    <inclusivemaxage />
    <inclusivemaxagetype>No limit</inclusivemaxagetype>
    <inclusivegender>Both males and females</inclusivegender>
    <healthyvolunteer>No</healthyvolunteer>
    <exclusivecriteria>-  Foreseeable poor compliance to the study procedures.

          -  Is a pregnant or lactating female.

          -  Is inappropriate for entry into this study in the judgment of the Investigator.

          -  Has certain serious illness or serious medical condition(s) described in the protocol.

          -  Has had certain other recent treatment e.g. major surgery, field radiation, received
             investigational agent, within the specified time frames prior to randomisation.

          -  Has previously received S 95005 or history of allergic reactions attributed to
             compounds of similar composition to S 95005 or any of its excipients.

          -  Has rare hereditary problems of galactose intolerance, the Lapp lactase deficiency or
             glucose-galactose malabsorption.

          -  Has contra-indication to bevacizumab or capecitabine.</exclusivecriteria>
  </eligibility>
  <trial_design>
    <studytype>Interventional</studytype>
    <purpose>Treatment</purpose>
    <allocation>Randomised controlled trial</allocation>
    <concealment />
    <sequence />
    <masking>Blinded (masking used)</masking>
    <assignment>Parallel</assignment>
    <designfeatures />
    <endpoint />
    <statisticalmethods />
    <masking1 />
    <masking2 />
    <masking3 />
    <masking4 />
    <patientregistry />
    <followup />
    <followuptype />
    <purposeobs />
    <duration />
    <selection />
    <timing />
  </trial_design>
  <recruitment>
    <phase>Phase 2</phase>
    <anticipatedstartdate />
    <actualstartdate>1/04/2016</actualstartdate>
    <anticipatedenddate />
    <actualenddate />
    <samplesize>150</samplesize>
    <actualsamplesize />
    <recruitmentstatus>Active, not recruiting</recruitmentstatus>
    <anticipatedlastvisitdate>1/04/2019</anticipatedlastvisitdate>
    <actuallastvisitdate />
    <dataanalysis />
    <withdrawnreason />
    <withdrawnreasonother />
    <recruitmentcountry>Australia</recruitmentcountry>
    <recruitmentstate />
    <hospital>Austin Hospital, Olivia Newton-John Cancer &amp; Wellness Centre - Heidelberg</hospital>
    <hospital>Western Health, Sunshine Hospital - St Albans</hospital>
    <postcode> - Heidelberg</postcode>
    <postcode> - St Albans</postcode>
    <countryoutsideaustralia>
      <country>Belgium</country>
      <state>Charleroi</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Belgium</country>
      <state>Leuven</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Belgium</country>
      <state>Liege</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Brazil</country>
      <state>Barretos</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Brazil</country>
      <state>Ijui</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Brazil</country>
      <state>Sao Jose do Rio Preto</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Denmark</country>
      <state>Copenhagen</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Denmark</country>
      <state>Odense</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>France</country>
      <state>Besan√ßon</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>France</country>
      <state>Paris</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>France</country>
      <state>Saint-Herblain</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Germany</country>
      <state>Berlin</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Germany</country>
      <state>Magdeburg</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Germany</country>
      <state>Munich</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Italy</country>
      <state>Bresse</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Italy</country>
      <state>Genova</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Italy</country>
      <state>Milan</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Italy</country>
      <state>Naples</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Italy</country>
      <state>Pisa</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Netherlands</country>
      <state>Amsterdam</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Netherlands</country>
      <state>Breda</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Netherlands</country>
      <state>Eindhoven</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Netherlands</country>
      <state>Groningen</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Netherlands</country>
      <state>Hilversum</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Netherlands</country>
      <state>Sittard-Geleen</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Netherlands</country>
      <state>Utrecht</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Netherlands</country>
      <state>Venlo</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Netherlands</country>
      <state>Zwolle</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Poland</country>
      <state>Krakow</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Poland</country>
      <state>Warszawa</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Russian Federation</country>
      <state>Moscow</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Russian Federation</country>
      <state>St Petersburg</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Spain</country>
      <state>Barcelona</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Spain</country>
      <state>Cordoba</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Spain</country>
      <state>Madrid</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Spain</country>
      <state>Malaga</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Spain</country>
      <state>Pamplona</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United Kingdom</country>
      <state>Glasgow</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United Kingdom</country>
      <state>Leicester</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United Kingdom</country>
      <state>London</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United Kingdom</country>
      <state>Manchester</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United Kingdom</country>
      <state>Middlesex</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United Kingdom</country>
      <state>Southampton</state>
    </countryoutsideaustralia>
  </recruitment>
  <sponsorship>
    <primarysponsortype>Other</primarysponsortype>
    <primarysponsorname>Institut de Recherches Internationales Servier</primarysponsorname>
    <primarysponsoraddress />
    <primarysponsorcountry />
  </sponsorship>
  <ethicsAndSummary>
    <summary>The main purpose of this study is to evaluate the progression-free survival (PFS) in patients
      receiving S 95005 + bevacizumab (experimental arm) or capecitabine + bevacizumab (control
      arm) as first-line treatment for unresectable metastatic colorectal cancer in patients
      non-eligible for intensive therapy.</summary>
    <trialwebsite>https://clinicaltrials.gov/show/NCT02743221</trialwebsite>
    <publication />
    <ethicsreview />
    <publicnotes />
  </ethicsAndSummary>
  <attachment />
  <contacts>
    <contact>
      <title />
      <name>Eric Van Custem, Prof</name>
      <address>Leuven Cancer Institute, University Hospitals Leuven</address>
      <phone />
      <fax />
      <email />
      <country />
      <type>Principal Investigator</type>
    </contact>
    <contact>
      <title />
      <name />
      <address />
      <phone />
      <fax />
      <email />
      <country />
      <type>Public Queries</type>
    </contact>
  </contacts>
</CT.GOV_Trial>